| |
AbCellera unlocks high-value drug classes, targets, and modalities, including T–cell engagers, antibody-drug conjugates, transmembrane proteins, and peptide-MHCs. Explore More. 
|
|
Today’s Big NewsFeb 2, 2024 |
| By Annalee Armstrong Regeneron wants to improve on obesity care with a muscle-preservation approach, while elsewhere, the biopharma charts a new course in cell therapy thanks to the acquisition of 2seventy's pipeline. |
|
|
|
By Max Bayer Bristol Myers Squibb is focused on integrating its new acquisitions, but CEO Chris Boerner said there's still interest in more development, which likely would center on bolt-on deals. |
By Nick Paul Taylor Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday, when the drugmaker axed a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline. |
By James Waldron In a second busy week of biotech IPOs, Alto Neuroscience and Fractyl Health will both be jumping onto the public markets this morning with their sights set on raking in over $100 million each. |
By Nick Paul Taylor AstraZeneca has the data to mount an attack on Pfizer’s dominance of a heart disease market. Friday, the Anglo-Swedish drugmaker reported positive top-line results from a phase 3 trial of acoramidis in Japan, teeing it up to file for regulatory approval in the country. |
By James Waldron Already reeling from the controversial termination of its CEO, Allarity Therapeutics has now been told that Novartis is rescinding the rights to a troubled cancer drug after the biotech failed to keep up with its payments. |
By Max Bayer,Gabrielle Masson After helping lead approval of Eisai, Biogen-partnered Alzheimer's med, Ivan Cheung will take the reins of NextPoint Therapeutics. 2seventy's reshuffle sends CSO to Regeneron as cell therapy unit leader. Sanofi swaps CFOs, naming ex-Nestle, Takeda financial chief. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Ayla Ellison,Conor Hale This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
By Fraiser Kansteiner Sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion in the third quarter. |
By Noah Tong The Federation of American Hospitals is pushing CMS for the inclusion of a star ratings quality measure that shows how often insurers overturn or uphold prior authorization denials. |
By Angus Liu Takeda paid $300 million upfront to license a blood disorder candidate. Lonza will close a biologics plant in China. A U.S. draft bill targets several Chinese biotech companies. And more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
